Phase I trial of hedgehog pathway inhibitor vismodegib (GDC-0449) in patients with refractory, locally advanced or metastatic solid tumors. [electronic resource]
Producer: 20110930Description: 2502-11 p. digitalISSN:- 1557-3265
- Abdominal Pain -- chemically induced
- Adult
- Aged
- Aged, 80 and over
- Anilides -- adverse effects
- Dose-Response Relationship, Drug
- Drug Resistance, Neoplasm
- Fatigue -- chemically induced
- Female
- Gene Expression Regulation, Neoplastic -- drug effects
- Hedgehog Proteins -- antagonists & inhibitors
- Humans
- Hyponatremia -- chemically induced
- Male
- Middle Aged
- Neoplasm Metastasis
- Neoplasm Staging
- Neoplasms -- drug therapy
- Pyridines -- adverse effects
- Reverse Transcriptase Polymerase Chain Reaction
- Signal Transduction -- drug effects
- Transcription Factors -- genetics
- Treatment Outcome
- Zinc Finger Protein GLI1
No physical items for this record
Publication Type: Clinical Trial, Phase I; Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
There are no comments on this title.
Log in to your account to post a comment.